Media

EASTGATE BIOTECH ANNOUNCES THAT PHARMACENTER LTD. WILL COMMENCE MARKETING THE COMPANY’S NUTRACEUTICAL PRODUCTS

May 26, 2015 by admin

PharmaCenter Ltd. successfully registered E-drops with the local health authority in Slovakia and placed an initial sample order for E-drops which is the company’s natural and herbal alternative that assists to rid the body of UTI infections painlessly and effectively without side effects of synthetic drugs. The initial sample order will be used for test marketing and launch in Slovakia initially before entering into the other respective markets.

Read more

EASTGATE BIOTECH RECEIVES PURCHASE ORDER FROM ITS CANADIAN DISTRIBUTOR FOR NUTRACEUTICAL PRODUCTS

March 11, 2015 by bnovak

SALT LAKE CITY and TORONTO, March 11, 2015 (PRNewswire/-) EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received a purchase order from ...

Read more

EASTGATE BIOTECH ENGAGES DISTRIBUTION COMPANY FOR ITS NUTRACEUTICAL PRODUCTS FOR CANADIAN MARKET

February 23, 2015 by bnovak

SALT LAKE CITY and TORONTO, February 23, 2015 (PRNewswire/-) EastGate Biotech Corp. (OTCBB: EBTI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules engages Preferred Nutrition...

Read more

EASTGATE BIOTECH PROVIDES UPDATE ON ITS PATENT PORTFOLIO

February 3, 2015 by bnovak

EastGate Biotech Patent Portfolio Update: SALT LAKE CITY and TORONTO, February 3, 2015 (PRNewswire/-) EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company exploring drug ...

Read more

GLUCORA, SUPPORT HEALTHY GLUCOSE METABOLISM, NPN

January 23, 2015 by bnovak

EASTGATE BIOTECH CORP. RECEIVES AN NPN (NATURAL PRODUCT NUMBER) FOR ITS PRODUCT GLUCORA, DESIGNED TO SUPPORT HEALTHY GLUCOSE METABOLISM NPN GRANTED BY THE NATURAL AND NON-PRESCRIPTION HEALTH PRODUCTS DIRECTORATE (NHPD) OF HEALTH CANADASALT LAKE CITY and TORONTO, January 23, 2015 (PRNewswire/-) EastGate Biotech Corp. ...

Read more

EASTGATE BIOTECH CORP. NAMES NEW PRESIDENT

January 20, 2015 by bnovak

SALT LAKE CITY and TORONTO, January 20, 2015 (PRNewswire/-) Eastgate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules has appointed ...

Read more

NEW STOCK SYMBOL ETBI

December 15, 2014 by bnovak

EASTGATE ACQUISITIONS ANNOUNCES NAME CHANGE TO EASTGATE BIOTECH CORP. AND NEW STOCK SYMBOL SALT LAKE CITY and TORONTO, December 15, 2014 (PRNewswire/-) Eastgate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel ...

Read more

Company’s Proprietary Intraoral Lorazepam Spray

November 3, 2014 by bnovak

EASTGATE ACQUISITIONS ANNOUNCES POSTER PRESENTATION OF THE COMPANY’S PROPRIETARY INTRAORAL LORAZEPAM SPRAY AT THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS (AAPS) CONFERENCE SALT LAKE CITY and TORONTO, November 3, 2014 (PRNewswire/-) EastGate Acquisitions Corporation ...

Read more

EASTGATE ACQUISITIONS AUGMENTS ITS SUB-MICRON SELF-NANOEMULSIFYING PLATFORM TECHNOLOGY

August 15, 2014 by bnovak

Broad spectrum of delivery forms is directed towards improving patient complianceSALT LAKE CITY and TORONTO, August 15 , 2014 (PRNewswire/-) EastGate ...

Read more

EASTGATE ACQUISITIONS ENTERS INTO A LICENSE AGREEMENT WITH PURINE PHARMA LLC FOR MARKETING AND DISTRIBUTION OF ITS NUTRACEUTICAL AND CONSUMER PRODUCT LINE

July 29, 2014 by bnovak

SALT LAKE CITY and TORONTO, September 29, 2014 (PRNewswire/-) EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of novel formulations and alternative dosage forms of existing biologically active molecules, announces that it has entered into a licensing ...

Read more
RSS Icon